Trial Profile
Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiving erythropoiesis-stimulating agents.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Apr 2018
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Anaemia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms PIERIAD STUDY
- 02 Apr 2018 New trial record